Medical

cost-effectiveness

Also found in: Dictionary, Wikipedia.

cost-ef·fec·tive·ness

(kawst-e-fekt'iv-nĕs)
The proportion between expense and the goods and services received for them.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
Mentioned in
References in periodicals archive
A cost-effectiveness model based on a previously published and validated analytic decision-tree (13) was used to compare the direct costs and outcomes of the three drugs.
The cost-effectiveness of antiretroviral therapy in the Caribbean was studied using the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) international model, an adaptation of the CEP AC US model, a state-transition simulation model of HIV disease in resource-limited settings.
It is tempting--and perhaps legitimate--to ask whether all the health interventions used in PAHO's technical cooperation programs would pass the test of cost-effectiveness. The results of such a test would, of course, be relative; some would emerge as more cost-effective than others.
Previous studies have examined the cost-effectiveness of influenza vaccination in various age groups (8-10).
The question to ask in cost-effectiveness analysis is: Which alternative returns the most value in relation to the overall cost?
Norheim draws attention to criticisms of earlier versions of DCP, notably the use of cost-effectiveness as a key criterion for decision-making to the exclusion of affordability, ethics, equity, legitimacy and human rights.
Equally importantly, evaluations of its cost-effectiveness, including economic evaluations of NM both as a replacement for and a complement to standard care must be undertaken.
He disclosed serving as the principal investigator of a National Cancer Institute study on cost-effectiveness analyses to determine reasonable options for cervical cancer screening.
Their finding was that a risk-stratified screening strategy could improve the benefit-to-harm ratio and the cost-effectiveness of the breast screening programme, with diminishing return with screening offered to women at lower risk.
As such, exclusion lists would purportedly reflect the value-based factors of clinical and cost-effectiveness. Pharmacy benefit managers establish clinical equivalency of drags in a therapeutic classification system in terms of safety and effectiveness.
(1) In this commentary, we use this example to highlight potential pitfalls of prioritizing cost-effectiveness in the application of HTA to the exclusion of other considerations, especially when estimates of cost-effectiveness are driven more by modelling than data.
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.